| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
NBI-31772 hydrate manufacturers
- NBI-31772
-
- $51.00
-
2026-07-27
- CAS:374620-70-9
- Purity: 99.83%
- Supply Ability: 10g
|
| | NBI-31772 hydrate Basic information |
| Product Name: | NBI-31772 hydrate | | Synonyms: | NBI-31772 hydrate;1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid;NBI-31772 - CAS 374620-70-9 - Calbiochem;inhibit,IGF-responsive diseases,IGF-1R,IGFBP,NBI-31772,Inhibitor;3-Isoquinolinecarboxylic acid, 1-(3,4-dihydroxybenzoyl)-6,7-dihydroxy-;NBI31772|||NBI 31772;NBI-31772, 10 mM in DMSO | | CAS: | 374620-70-9 | | MF: | C17H11NO7 | | MW: | 341.27 | | EINECS: | | | Product Categories: | | | Mol File: | 374620-70-9.mol |  |
| | NBI-31772 hydrate Chemical Properties |
| Boiling point | 764.7±60.0 °C(Predicted) | | density | 1.696±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMF: 30 mg/ml; DMSO: 20 mg/ml; Ethanol: 10 mg/ml; PBS (pH 7.2): 0.14 mg/ml | | form | Greenish-yellow solid | | pka | 6.68±0.20(Predicted) | | color | Light yellow to brown |
| | NBI-31772 hydrate Usage And Synthesis |
| Uses | NBI-31772 is an insulin-like growth factor-I binding protein (IGFBP) ligand. | | in vivo | NBI-31772 (5-100 μg; siv; administered at the onset of ischemia) dose-dependently reduces total infarct volume and cortical infarct volume at the onset of ischemia in rats with middle cerebral artery occlusion (MCAO) model[2].
NBI-31772 (50 μg; i.v.; administered 0, 1, 2, or 3 hours after MCAO) reduces cortical infarct size and brain swelling in rats with intraluminal suture MCAO model[2].
NBI-31772 (0.4 μM/strip; i.p.; 4 h) induces germinal vesicle rupture in zebrafish[4]. | Animal Model: | MCAO model rats[2] | | Dosage: | 5, 50 and 100 μg | | Administration: | siv; Drug administration during ischemic episodes | | Result: | Had similar effects on total lesion volume at the 50 and 100 μg doses.
Affected striatal lesion volume at the 50 μg dose. |
| Animal Model: | Intraluminal suture MCAO model rats[2] | | Dosage: | 50 μg | | Administration: | i.v.; Administration 0, 1, 2, or 3 hours after MCAO | | Result: | The greatest lesion reduction was observed when the drug was administered immediately after MCAO. |
| | storage | Store at -20°C |
| | NBI-31772 hydrate Preparation Products And Raw materials |
|